Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183347 | Anti-TAT226 antibodies and immunoconjugates Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided. ... | 05/22/2012 |
| 8183029 | Replicable expression vector for bacterial expression of a mammalian polypeptide Refractile particles containing a heterologous polypeptide as an insoluble aggregate are recovered from bacterial periplasm. The process involves culturing bacterial cells so as to express nucleic acid encoding phage lysozyme and nucleic acid encoding the heterologo... | 05/22/2012 |
| 8163287 | Combination therapy of her expressing tumors The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors. ... | 04/24/2012 |
| 8158762 | Anti-factor B antibodies and their uses The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists. ... | 04/17/2012 |
| 8147827 | Tumor treatment The invention concerns an improved method for treating tumor, including cancer, which combines the administration of a chemotherapeutic agent and an antagonist of a gene product the expression of which is upregulated by the chemotherapeutic agent. The invention furt... | 04/03/2012 |
| 8137671 | Anti-IL-17F antibodies This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and ... | 03/20/2012 |
| 8131480 | Construction of diverse synthetic peptide and polypeptide libraries The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for ... | 03/06/2012 |
| 8114967 | Constructs and libraries comprising antibody surrogate light chain sequences The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chai... | 02/14/2012 |
| 8110548 | Method for treating cartilage disorders The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-bindin... | 02/07/2012 |
| 8088386 | Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders. ... | 01/03/2012 |
| 8076066 | Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the... | 12/13/2011 |
| 8075892 | Treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an an... | 12/13/2011 |
| 8075890 | Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. ... | 12/13/2011 |
| 8075888 | Methods of treatment using antibodies to IL-17 homologous polypeptides The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molec... | 12/13/2011 |
| 8068990 | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth ... | 11/29/2011 |
| 8062855 | Assay methods and materials The invention relates to assays in which complexes between an analyte and a binding agent specific for the analyte are detected by a reporter molecule, which is capable of binding to the binding agent when the binding agent is complexed with analyte but not when the... | 11/22/2011 |
| 8053551 | Serpentine transmembrane antigens expressed in human cancers and uses therefor Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” ... | 11/08/2011 |
| 8044017 | Protein purification A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants. ... | 10/25/2011 |
| 8034342 | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric ... | 10/11/2011 |
| 8030023 | Nucleic acid encoding DR5 antibodies and uses thereof The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer. ... | 10/04/2011 |
| 8029783 | DR5 antibodies and articles of manufacture containing same The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer. ... | 10/04/2011 |
| 8013135 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently,... | 09/06/2011 |
| 8012937 | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 ... | 09/06/2011 |
| 8012473 | C3b antibodies and methods for the prevention and treatment of complement-associated disorders The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies. ... | 09/06/2011 |
| 8008442 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently,... | 08/30/2011 |
| 8007798 | Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) an... | 08/30/2011 |
| 8007791 | Prevention and treatment of complement-associated eye conditions The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists. ... | 08/30/2011 |
| 7993834 | Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of ... | 08/09/2011 |
| 7968307 | Serpentine transmembrane antigens expressed in human cancers and uses thereof Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” ... | 06/28/2011 |
| 7956237 | Gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245,... | 06/07/2011 |
| 7951583 | Optical scanning system A scanning sensor system 100, methods and kits for use thereof including a switchable light source 102, a detector 106, a substrate 104 and a plurality of optical sensing sites 112 are provided. Substrate 104 is coupled to a... | 05/31/2011 |
| 7947650 | Article of manufacture The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-bindin... | 05/24/2011 |
| 7947459 | Serpentine transmembrane antigens expressed in human cancers and uses thereof Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” ... | 05/24/2011 |
| 7947276 | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently,... | 05/24/2011 |
| 7943329 | Modulators of neuronal regeneration The present invention provides methods and compositions related to CNS function and diseases. ... | 05/17/2011 |
| 7939503 | Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently,... | 05/10/2011 |
| 7931902 | Gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO3600... | 04/26/2011 |
| 7930109 | Crystal structure of CRIg and C3b:CRIg complex The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further c... | 04/19/2011 |
| 7928201 | Serpentine transmembrane antigens expressed in human cancers and uses thereof Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” ... | 04/19/2011 |
| 7919672 | Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several h... | 04/05/2011 |
